Protara Therapeutics (TARA) Cash from Investing Activities (2013 - 2026)

Protara Therapeutics (TARA) has reported Cash from Investing Activities for 14 consecutive years, with -$14.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 74.77% year-over-year to -$14.7 million; the TTM figure through Mar 2026 stood at -$95.9 million (down 53.87% YoY), while the FY2025 annual figure was -$139.5 million, down 828.22% from the prior year.
• Cash from Investing Activities improved to -$14.7 million in Q1 2026 per TARA's latest filing, from -$26.9 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $23.1 million in Q1 2024 and bottomed at -$58.4 million in Q1 2025.
• Historically, Cash from Investing Activities has averaged -$3.9 million across 5 years, with a median of $2.9 million in 2024.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities jumped 17701.87% — and 2025, when it plunged 1720.48%.
• Protara Therapeutics' Cash from Investing Activities stood at -$18.3 million in 2022, then soared by 179.14% to $14.5 million in 2023, then jumped by 54.98% to $22.5 million in 2024, then plunged by 219.59% to -$26.9 million in 2025, then soared by 45.29% to -$14.7 million in 2026.
• Business Quant data shows TARA's Cash from Investing Activities at -$14.7 million in Q1 2026, -$26.9 million in Q4 2025, and -$6.5 million in Q3 2025.